A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML)

Clinical trial NCT03730012 · COMPLETED

Trial details

NCT number: NCT03730012
Sponsor: Astellas Pharma Global Development, Inc.
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Acute Myeloid Leukemia (AML)Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation

Start date: 2019-06-19
Primary completion: 2021-05-14
Enrollment: 11

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.